TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35398787

Group type: EXPERIMENTAL
Intervention: Low serum albumin levels in children with severe malnutrition
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Markers of extracellular matrix (ECM) degradation
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Albumin-dependent mechanisms
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: ECM integrity
Number of subjects: 242
Study: 35398844

Group type: EXPERIMENTAL
Intervention: Hiccups
Number of subjects: 1

Group type: COMPARATOR
Intervention: Spontaneous breaths
Number of subjects: 1
Study: 35399055

Group type: EXPERIMENTAL
Intervention: Proactive primary care intervention
Number of subjects: 779

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 779
Study: 35399083

Group type: EXPERIMENTAL
Intervention: Mobile brain perfusion ultrasound (BPU) using SONAS® device
Number of subjects: 12
Study: 35399240

Group type: EXPERIMENTAL
Intervention: Surgical resection of IPN (expected n=94)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Follow-up group (expected n=282)
Number of subjects: 1253
Study: 35399565

Group type: EXPERIMENTAL
Intervention: Three-dimensionally printed navigational template-guided fine-needle aspiration (FNA)
Number of subjects: 18
Study: 35399676

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency (VAD) group
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Marginal vitamin A deficiency (MVAD) group
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Vitamin A normal (NVA) group
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Post-laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 976
Study: 35399927

Group type: EXPERIMENTAL
Intervention: Fat mass
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Free leptin index
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Interaction between fat mass and free leptin index
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Interaction between fat mass and adiponectin
Number of subjects: 230
Study: 35399955

Group type: EXPERIMENTAL
Intervention: Baseline and trajectories of the triglyceride-glucose (TyG) index
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: High and very high TyG index trajectories
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: TyG index quartile characterization
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 1815
Study: 35400203

Group type: EXPERIMENTAL
Intervention: Tortuous group (extracranial or cavernous ICA tortuosity)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Nontortuous group
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Tortuous group
Number of subjects: 370
Study: 35400633

Group type: EXPERIMENTAL
Intervention: Edoxaban treatment
Number of subjects: 858
Study: 35400997

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1505

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1505
Study: 35401389

Group type: EXPERIMENTAL
Intervention: Exercise training during chemotherapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: First line chemotherapy without exercise training
Number of subjects: 126
Study: 35401418

Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation (TPS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 30
Study: 35402241

Group type: EXPERIMENTAL
Intervention: Niraparib (200mg or 300mg per day) for two cycles (4 weeks/cycle)
Number of subjects: 53
Study: 35402359

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) during immunization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care without VR
Number of subjects: 30
Study: 35402736

Group type: EXPERIMENTAL
Intervention: READyR Program
Number of subjects: 11
Study: 35402894

Group type: EXPERIMENTAL
Intervention: LEM 5 mg
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: LEM 10 mg
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 35402913

Group type: EXPERIMENTAL
Intervention: Nivolumab plus radiotherapy plus temozolomide (NIVO+RT+TMZ)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Nivolumab plus radiotherapy (NIVO+RT)
Number of subjects: 136
Study: 35403243

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1150
Study: 35403375

Group type: EXPERIMENTAL
Intervention: Activity Card Sort, Second Edition (ACS)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Multi-Dimensional Fatigue Inventory
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Lower Extremity Functional Scale
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Upper Extremity Functional Index
Number of subjects: 47
Study: 35403374

Group type: EXPERIMENTAL
Intervention: HFpEF (n=137)
Number of subjects: 547
Study: 35403446

Group type: EXPERIMENTAL
Intervention: Training workshop on the Screening Tool for Autism in Toddlers
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Use of the Screening Tool for Autism in Toddlers
Number of subjects: 69
Study: 35403503

Group type: EXPERIMENTAL
Intervention: hs-cTnT elevation
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: BNP elevation
Number of subjects: 233

Group type: COMPARATOR
Intervention: Pathological findings on CMR
Number of subjects: 233
Study: 35403679

Group type: EXPERIMENTAL
Intervention: Significant long-COVID fatigue
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Peak exercise heart rate
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Oxygen consumption per kilogram
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Long-COVID memory impairment
Number of subjects: 141
Study: 35403786

Group type: EXPERIMENTAL
Intervention: Microneedling procedures (4 monthly sessions)
Number of subjects: 35
Study: 35403818

Group type: EXPERIMENTAL
Intervention: Combined pancreatic islet-lung transplantation
Number of subjects: 10
Study: 35403852

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 3968

Group type: COMPARATOR
Intervention: Non-PVI
Number of subjects: 3968
Study: 35404075

Group type: EXPERIMENTAL
Intervention: Delamanid 100 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid 50 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delamanid 25 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimized Background Regimen (OBR)
Number of subjects: 0
Study: 35404255

Group type: EXPERIMENTAL
Intervention: PACO service for 8 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 32
Study: 35404384

Group type: EXPERIMENTAL
Intervention: Swiss HCVree Trial
Number of subjects: 4641

Group type: EXPERIMENTAL
Intervention: Swiss HCVree Post screen
Number of subjects: 4641

Group type: EXPERIMENTAL
Intervention: HCV incidence
Number of subjects: 4641
Study: 35404402

Group type: EXPERIMENTAL
Intervention: Adagrasib (MRTX849) 600 mg twice daily
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Adagrasib (MRTX849)
Number of subjects: 2
Study: 35404455

Group type: EXPERIMENTAL
Intervention: Excessive weight (EW), BMI ≥25
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal weight (NW), BMI <25
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Breastfeeding duration ≥9 months
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Human milk (HM) insulin concentrations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Human milk (HM) leptin concentrations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Parental feeding restriction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Healthy eating index (HEI)
Number of subjects: 56
Study: 35404683

Group type: EXPERIMENTAL
Intervention: 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET)
Number of subjects: 2290

Group type: EXPERIMENTAL
Intervention: Guiding systemic treatment by both RS and ET response
Number of subjects: 2290
Study: 35404977

Group type: EXPERIMENTAL
Intervention: Community-based cross-sectional study with self-reported survey and oral fluid testing for HIV antibodies.
Number of subjects: 0
Study: 35405009

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCL2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRRX2-related gene signature
Number of subjects: 0
Study: 35405360

Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with low PD-L1 expression (TPS < 50%)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Crizotinib treatment with high PD-L1 expression (TPS ≥ 50%)
Number of subjects: 128
Study: 35405725

Group type: EXPERIMENTAL
Intervention: Continuous capnography and pulse oximetry monitoring
Number of subjects: 1335
Study: 35406387

Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs) composed of gene-regulatory small interfering (si)RNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs) carrying unmethylated CpG-rich oligonucleotides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spherical Nucleic Acids (SNAs)
Number of subjects: 0
Study: 35406491

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy CA27.29 assessment
Number of subjects: 3754

Group type: EXPERIMENTAL
Intervention: Post-chemotherapy CA27.29 assessment
Number of subjects: 3754
Study: 35406565

Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 338

Group type: COMPARATOR
Intervention: Entrectinib
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 338
Study: 35406806

Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccination
Number of subjects: 0
Study: 35407553

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg daily for 23 patients, 30 mg daily for 2 patients)
Number of subjects: 25
Study: 35407655

Group type: EXPERIMENTAL
Intervention: Daily bedside echocardiographic monitoring (JetEcho)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 250
Study: 35409640

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Missed physician visits
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Deterioration in sleep time
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Increase in screen time
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Decrease in physical activity
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: Psychological distress (Kessler-6 score ≥ 5)
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Urban living place
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Worse self-reported mental health
Number of subjects: 1274

Group type: COMPARATOR
Intervention: K6 score ≥ 5
Number of subjects: 1274
Study: 35410115

Group type: EXPERIMENTAL
Intervention: Left uterine displacement (LUD) during baseline with spinal anesthesia (SA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Baseline without left uterine displacement (LUD)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: After spinal anesthesia with left uterine displacement (LUD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: After spinal anesthesia without left uterine displacement (LUD)
Number of subjects: 46
Study: 35410197

Group type: EXPERIMENTAL
Intervention: Oral ibandronate 150 mg once monthly for 1 year
Number of subjects: 120
Study: 35410310

Group type: EXPERIMENTAL
Intervention: Self-reported adverse childhood experiences (ACE) before the age of 18
Number of subjects: 5000
Study: 35410326

Group type: EXPERIMENTAL
Intervention: Unknown partner HIV status
Number of subjects: 8086

Group type: EXPERIMENTAL
Intervention: Use of alcohol/drugs prior to intercourse (sometimes)
Number of subjects: 8086

Group type: EXPERIMENTAL
Intervention: Use of alcohol/drugs prior to intercourse (always)
Number of subjects: 8086

Group type: EXPERIMENTAL
Intervention: Any HIV treatment literacy
Number of subjects: 8086
Study: 35410325

Group type: EXPERIMENTAL
Intervention: PD-L1 blockade
Number of subjects: 0
Study: 35410449

Group type: EXPERIMENTAL
Intervention: CoMDA (Cognition in Movement Disorders Assessment)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: CoMDA-ML (Quadratic Discriminant Analysis algorithm)
Number of subjects: 500
Study: 35410894

Group type: EXPERIMENTAL
Intervention: Conservative initial management in 78% of patients
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Type 2 intramural haematoma (IMH)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Proximal vessel involvement
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Previous history of hypothyroidism
Number of subjects: 389
Study: 35410912

Group type: EXPERIMENTAL
Intervention: Body iron stores (BIS) measured by serum ferritin and serum transferrin receptor
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Daily smoking, hypertension, and increased resting heart rate
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 789
Study: 35410913

Group type: EXPERIMENTAL
Intervention: Hyperemic microvascular resistance (HMR) in lesions with FFR>0.80 and CFR<2.0 (n=99)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Hyperemic microvascular resistance (HMR) in lesions with FFR≤0.80 and CFR≥2.0 (n=68)
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: FFR value
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Increased HMR
Number of subjects: 430
Study: 35410928

Group type: EXPERIMENTAL
Intervention: Swahili language Ada Symptom Assessment Application (SAA) used before usual care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care provided by healthcare practitioners after using the SAA.
Number of subjects: 0
Study: 35411075

Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (AAV5-hFVIII-SQ)
Number of subjects: 5
Study: 35411113

Group type: EXPERIMENTAL
Intervention: Cerenkov luminescence imaging (CLI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care nuclear imaging
Number of subjects: 0
Study: 35411349

Group type: EXPERIMENTAL
Intervention: Dupilumab plus standard of care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 40
Study: 35412071

Group type: EXPERIMENTAL
Intervention: Polytraumatized patients over time
Number of subjects: 953
Study: 35412069

Group type: EXPERIMENTAL
Intervention: Mirabegron treatment for UUI
Number of subjects: 83
Study: 35412216

Group type: EXPERIMENTAL
Intervention: batoclimab 680 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: batoclimab 340 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: batoclimab groups
Number of subjects: 30
Study: 35412356

Group type: EXPERIMENTAL
Intervention: Camostat mesylate 200 mg dosed four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camostat mesylate at 3-fold higher dosing
Number of subjects: 0
Study: 35412607

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Number of subjects: 0
Study: 35412950

Group type: EXPERIMENTAL
Intervention: Isolation and culture protocols for hAMSCs
Number of subjects: 0
Study: 35413027

Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 294
Study: 35413092

Group type: EXPERIMENTAL
Intervention: Romiplostim (1 μg/kg titrated to 10 μg/kg, administered weekly)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 203
Study: 35413279

Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg/dose IV q6h) for 7 days
Number of subjects: 12
Study: 35413473

Group type: EXPERIMENTAL
Intervention: Reliever use before and after exacerbations
Number of subjects: 0
Study: 35413779

Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography (MVUS) with MVUS-VI cutoff value of 24.95%
Number of subjects: 101

Group type: COMPARATOR
Intervention: Conventional color Doppler (CD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Power Doppler (PD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography (MVUS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography vascularity indices (MVUS-VI)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MVUS
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MVUS-VI
Number of subjects: 101
Study: 35413789

Group type: EXPERIMENTAL
Intervention: Elevated NT-proCNP
Number of subjects: 309

Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: NT-proCNP
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: STS-Score
Number of subjects: 309
Study: 35413794

Group type: EXPERIMENTAL
Intervention: hs-cTnT ≥14 ng/L
Number of subjects: 5199

Group type: COMPARATOR
Intervention: hs-cTnT <14 ng/L
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥300 pg/ml
Number of subjects: 5199

Group type: COMPARATOR
Intervention: NT-proBNP <300 pg/ml
Number of subjects: 5199

Group type: EXPERIMENTAL
Intervention: Both hs-cTnT ≥14 ng/L and NT-proBNP ≥300 pg/ml
Number of subjects: 5199
Study: 35413865

Group type: EXPERIMENTAL
Intervention: Elderly adults with SSD (measured by Somatic Symptom Scale-China)
Number of subjects: 6814

Group type: EXPERIMENTAL
Intervention: Elderly adults with SSD
Number of subjects: 6814

Group type: COMPARATOR
Intervention: Non-elderly adults (2206 participants)
Number of subjects: 6814
Study: 35413904

Group type: EXPERIMENTAL
Intervention: EasyScan Go device
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: EasyScan Go device with good quality slides
Number of subjects: 2250
Study: 35413976

Group type: EXPERIMENTAL
Intervention: ParTNerSTEPs program (comprehensive transfer program for parents)
Number of subjects: 0
Study: 35413985

Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning with thiotepa-busulfan-fludarabine
Number of subjects: 101
Study: 35414025

Group type: EXPERIMENTAL
Intervention: Small-molecule compounds targeting regulated cell death (RCD) subroutines, including narciclasine, torin-1 combined with chloroquine, ONC201, and NCT03733119.
Number of subjects: 0
Study: 35414591

Group type: EXPERIMENTAL
Intervention: Enoblituzumab (15 mg/kg) plus pembrolizumab (2 mg/kg) every 3 weeks
Number of subjects: 133
Study: 35415385

Group type: EXPERIMENTAL
Intervention: Enhanced food bank intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard food bank services
Number of subjects: 0
Study: 35415708

Group type: EXPERIMENTAL
Intervention: Intervention from phase 3 randomized trials (LIBERTY 1 and 2)
Number of subjects: 30
Study: 35415707

Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) implementation
Number of subjects: 0
Study: 35415885

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) subjects undergoing severe iatrogenic hypoglycaemia
Number of subjects: 46
Study: 35415928

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived stem cells (ADSCs)
Number of subjects: 12
Study: 35416053

Group type: EXPERIMENTAL
Intervention: Avelumab maintenance treatment plus best supportive care
Number of subjects: 700

Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 700
Study: 35416669

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and palbociclib
Number of subjects: 0
Study: 35416710

Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment
Number of subjects: 289
Study: 35416787

Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation table with serious games (12 sessions)
Number of subjects: 2
Study: 35416975

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35417089

Group type: EXPERIMENTAL
Intervention: Echocardiographic red flags for AC (apical sparing or a combination of ≥2 other red flags)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Final diagnosis of amyloid cardiomyopathy (AC)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Transthyretin-related AC (ATTR-AC)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Light chain-related AC (AL-AC)
Number of subjects: 217
Study: 35417425

Group type: EXPERIMENTAL
Intervention: Intraoperative F io2 median of 0.46 (range 0.32-0.94)
Number of subjects: 6588

Group type: COMPARATOR
Intervention: Controlled trials with 80% vs 30% oxygen
Number of subjects: 6588

Group type: EXPERIMENTAL
Intervention: Intraoperative F io2 median of 0.46
Number of subjects: 6588
Study: 35417530

Group type: EXPERIMENTAL
Intervention: Combination treatment of HDAC inhibitors (panobinostat or romidepsin) and ClpP activators (ONC206 and ONC212)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ClpP activators (mutant ClpP Y118A, ONC206, ONC212)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatment of HDAC inhibitors and imipridones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of ClpP protease or ectopic expression of ClpP D190A mutant
Number of subjects: 0
Study: 35417637

Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (200 mg once daily, 400 mg once daily, 300 mg twice daily, 400 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (400 mg twice daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (all dose levels)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Number of subjects: 60
Study: 35417638

Group type: EXPERIMENTAL
Intervention: Mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 35417717

Group type: EXPERIMENTAL
Intervention: Potassium antimony tartrate (PAT)
Number of subjects: 0
Study: 35417791

Group type: EXPERIMENTAL
Intervention: Increased pain severity
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Increased pain interference
Number of subjects: 1461
Study: 35418030

Group type: EXPERIMENTAL
Intervention: SCC (squamous cell carcinoma)
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: AC (adenocarcinoma)
Number of subjects: 1291

Group type: COMPARATOR
Intervention: Comparison between SCC and AC
Number of subjects: 1291